2.82
4.83%
+0.13
Immutep Limited ADR stock is currently priced at $2.82, with a 24-hour trading volume of 315.05K.
It has seen a +4.83% increased in the last 24 hours and a +11.90% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.68 pivot point. If it approaches the $2.89 resistance level, significant changes may occur.
Previous Close:
$2.69
Open:
$2.78
24h Volume:
315.05K
Market Cap:
$335.25M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-12.55
EPS:
-0.2247
Net Cash Flow:
-
1W Performance:
+6.42%
1M Performance:
+11.90%
6M Performance:
+48.42%
1Y Performance:
+73.54%
Immutep Limited ADR Stock (IMMP) Company Profile
Name
Immutep Limited ADR
Sector
Industry
Phone
61 2 8315 7003
Address
95 Pitt Street, Level 12, Sydney, NSW
Immutep Limited ADR Stock (IMMP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-03-21 | Initiated | Ladenburg Thalmann | Buy |
Jul-16-21 | Resumed | Maxim Group | Buy |
Sep-28-18 | Initiated | B. Riley FBR | Buy |
Feb-15-18 | Reiterated | Maxim Group | Buy |
Immutep Limited ADR Stock (IMMP) Latest News
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
GlobeNewswire Inc.
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
GlobeNewswire Inc.
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
GlobeNewswire Inc.
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
GlobeNewswire Inc.
Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer
GlobeNewswire Inc.
Immutep Limited ADR Stock (IMMP) Financials Data
There is no financial data for Immutep Limited ADR (IMMP). Check out other stocks for more information.
About Immutep Limited ADR
Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company's lead product candidate is eftilagimod alpha (efti) with KEYTRUDA therapy, an antigen presenting cell activator, which is in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer, as well as in a Phase I combination therapy trial in metastatic melanoma. Its other products include IMP731, a LAG-3 depleting antibody, which is in a Phase I clinical trial for use in autoimmune diseases; IMP701, a LAG-3 antagonist antibody that is in a Phase I/II clinical trial, which is used for the treatment of cancer; and IMP761, an agonist of LAG-3 for treating autoimmune diseases. The company has operations in Europe, Australia, and the United States. Immutep Limited has a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., to evaluate the combination of efti with avelumab, a human anti-PD-L1 antibody, in patients with advanced solid malignancies; and partnerships with GlaxoSmithKline, Novartis, and EOC Pharma for the development of LAG-3 product candidates. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is headquartered in Sydney, Australia.
Cap:
|
Volume (24h):